Dendritic cells (DCs) are the most potent antigen-presenting cells capable of priming naïve T cells and are therefore essential tools in the activation of immune responses to tumors. They can be generated in vitro from CD14+ peripheral blood or cord blood derived monocytes through a maturation process. It is essential monocyte-derived DCs (Mo-DCs) maintain their functional capacity – the launching of Ag-specific immunity – leading to T cell proliferation and polarization into effector T cells. Serum and undefined components found in animal- or human-derived raw materials can impact this functional capacity. PRIME-XV Dendritic Cell Maturation CDM provides a robust process to generate Mo-DCs in chemically-defined culture conditions thereby maintaining their capacity to induce T cell response.
The PRIME-XV family of products is designed to simplify the transition to clinical production while adhering to global and regional regulatory standards. Irvine Scientific understands that adherence to a stringent Quality Management System including a robust Raw Material Program are critical to ensure traceability, consistency, and reliable performance in supporting immunotherapy applications.
To facilitate clinical applications and scale-up, both PRIME-XV Dendritic Cell Maturation CDM is available for custom formulation and packaging.